Adjuvant systemic therapy of breast cancer
The first procedure in primary breast cancer is usually the surgical excision of the tumor. However, a medical therapy is necessary in almost all patients to treat the systemic component of the disease. Which medical approach is recommended depends on the biology of the tumor itself. Endocrine-respo...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 3, 2011
|
| In: |
Breast care
Year: 2011, Volume: 6, Issue: 3, Pages: 179-183 |
| ISSN: | 1661-3805 |
| DOI: | 10.1159/000329336 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000329336 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/329336 
|
| Author Notes: | Florian Schuetz (Department of Gynecology and Obstetrics, Heidelberg University Hospital, Germany) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1820168050 | ||
| 003 | DE-627 | ||
| 005 | 20230710104647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221027s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000329336 |2 doi | |
| 035 | |a (DE-627)1820168050 | ||
| 035 | |a (DE-599)KXP1820168050 | ||
| 035 | |a (OCoLC)1389761633 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schütz, Florian |d 1972- |e VerfasserIn |0 (DE-588)12303387X |0 (DE-627)082307229 |0 (DE-576)293528810 |4 aut | |
| 245 | 1 | 0 | |a Adjuvant systemic therapy of breast cancer |c Florian Schuetz (Department of Gynecology and Obstetrics, Heidelberg University Hospital, Germany) |
| 264 | 1 | |c June 3, 2011 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.10.2022 | ||
| 520 | |a The first procedure in primary breast cancer is usually the surgical excision of the tumor. However, a medical therapy is necessary in almost all patients to treat the systemic component of the disease. Which medical approach is recommended depends on the biology of the tumor itself. Endocrine-responsive tumors must be treated by an endocrine therapy according to their menopausal status. In HER2/neu-overexpressing tumors, the monoclonal antibody trastuzumab is part of the standard treatment in combination with chemotherapy. Hormone receptor-negative and non-HER2/neu-overexpressing tumors as well as endocrine-responsive tumors with a high proliferation index or additional risk factors must be treated with chemotherapy as well. This review article gives further information about the available agents and schedules. | ||
| 546 | |a Text englisch, Zusammenfassung deutsch | ||
| 773 | 0 | 8 | |i Enthalten in |t Breast care |d Basel : Karger, 2006 |g 6(2011), 3, Seite 179-183 |h Online-Ressource |w (DE-627)501078142 |w (DE-600)2205941-6 |w (DE-576)276272617 |x 1661-3805 |7 nnas |a Adjuvant systemic therapy of breast cancer |
| 773 | 1 | 8 | |g volume:6 |g year:2011 |g number:3 |g pages:179-183 |g extent:5 |a Adjuvant systemic therapy of breast cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000329336 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/329336 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221027 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 12303387X |a Schütz, Florian |m 12303387X:Schütz, Florian |d 910000 |d 910400 |e 910000PS12303387X |e 910400PS12303387X |k 0/910000/ |k 1/910000/910400/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1820168050 |e 420272996X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Florian Schuetz (Department of Gynecology and Obstetrics, Heidelberg University Hospital, Germany)"]},"origin":[{"dateIssuedDisp":"June 3, 2011","dateIssuedKey":"2011"}],"id":{"doi":["10.1159/000329336"],"eki":["1820168050"]},"physDesc":[{"extent":"5 S."}],"relHost":[{"part":{"extent":"5","volume":"6","text":"6(2011), 3, Seite 179-183","issue":"3","pages":"179-183","year":"2011"},"pubHistory":["1.2006 -"],"language":["eng"],"recId":"501078142","disp":"Adjuvant systemic therapy of breast cancerBreast care","note":["Gesehen am 04.04.2019"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Breast care","subtitle":"multidisciplinary journal for research, diagnosis and therapy","title_sort":"Breast care"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2205941-6"],"eki":["501078142"],"issn":["1661-3805"]},"origin":[{"publisherPlace":"Basel","publisher":"Karger","dateIssuedKey":"2006","dateIssuedDisp":"2006-"}]}],"person":[{"given":"Florian","family":"Schütz","role":"aut","display":"Schütz, Florian","roleDisplay":"VerfasserIn"}],"title":[{"title":"Adjuvant systemic therapy of breast cancer","title_sort":"Adjuvant systemic therapy of breast cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 27.10.2022"],"recId":"1820168050","language":["eng"]} | ||
| SRT | |a SCHUETZFLOADJUVANTSY3201 | ||